Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer-Reference-Cited by-同舟云学术

Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer

Published:2024-05-02 Issue: Volume: Page:
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Ouyang Wenhao¹,Liu Yajing¹,Huang Hong²,Tan Yujing³,Huang Zhenjun¹,Jia Xueyuan⁴,Yu Yunfang¹⁴,Yao Herui¹

Affiliation:

1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Breast Tumor Centre, Phase I Clinical Trial Centre, Yat-Sen Supercomputer Intelligent Medical Joint Research Institute, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong, China

2. School of Medicine, Guilin Medical University, Guilin 541000, Guangxi, China

3. Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China

4. Faculty of Medicine, Macau University of Science and Technology, Taipa 999078, Macao, P.R. China

Publisher

Impact Journals, LLC

Reference44 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.;Bray;CA Cancer J Clin,2021

2. Cancer statistics in China, 2015.;He;CA Cancer J Clin,2016

3. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.;Topuzov;Lancet,2014

4. The Unfolded Protein Response and Cell Fate Control.;Papa;Mol Cell,2018

5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.;Hill;Lancet,2010